
The CHMP recommended authorization for patients aged 12 and older, with a European Commission decision expected in about two months.
Novartis said a European Medicines Agency committee recommended Cosentyx for adolescents aged 12 and older with active, moderate to severe hidradenitis suppurativa. The recommendation applies to patients who have not responded adequately to conventional systemic therapy.
The CHMP’s positive opinion draws on adult efficacy and safety data, pediatric trial data from other approved uses, and modeling of weight-based dosing, Novartis said. The company said that, if approved, Cosentyx would be the only IL-17A inhibitor authorized for adolescent HS in Europe.
The European Commission is expected to make a final decision in about two months.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.